The tweet was deleted by the author.
But we saved everything 🙂.
Allogene Therapeutics announced an interim futility analysis for its ALPHA3 allogeneic CART cell therapy program during SITC2026.
The company also outlined the continued expansion of its allogeneic CART product portfolio, aiming to improve patient access in cancer treatment and related areas. CEO Zachary Roberts, MD, PhD, delivered the update as part of ongoing efforts in advancing cell therapy innovation.
View post on X Loading...